Abstract library

418 results for "doubling time".
#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Authors:
#1380 Assessment of the Growth Rate of Paragangliomas Related to SDHx Gene Mutations Using Computed Tomography.
Introduction: SDHx mutations are associated with a lifelong risk of multifocal paragangliomas (PGL), so patients need regular follow-up examinations.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Ilona Michałowska
Authors:
#1764 Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience
Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Authors:
Keywords: TNE, TKI
#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
Authors:
#1180 A Novel Human Cell Line from Familial Medullary Thyroid Carcinoma
Introduction: Cell lines from hereditary medullary thyroid carcinomas (MTC) are very rare, therefore, there is a substantial need to establish new cell lines. Here, we present a novel familial MTC (FMTC) cell line, designated SCHWE.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Roswitha Pfragner
Authors:
#1183 Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line
Introduction: The development of new therapeutic strategies for patients with pancreatic neuroendocrine tumours is impaired by the paucity of suitable pre-clinical models. Although the two available tumour cell lines BON and QGP have a neuroendocrine phenotype, the proliferation rate is too high for a well differentiated neuroendocrine tumour.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors:
#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model
Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors:
Keywords: pNET, insulinoma, SSTR
#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study
Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Christof Rottenburger
Authors:
#2186 Management of Aggressive Medullary Thyroid Cancer
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the C cells of thyroid gland characterized by significant morbidity.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Chiara Bima
Authors:
#2201 Early Prognostic Factors in Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) prognosis has been related with several variables, being calcitonin doubling time one of the most important prognostic factor. However, it is not evaluable in the early postoperative period.
Conference: 15th Annual ENETS conference (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Jose Luis Muñoz de Nova
Authors: